New in Immunology
Our new Primary Immunodeficiency (PID) and Primary Ciliary Dyskinesia (PCD) Panel consists of 308 carefully curated genes.
Join our cardiology webinar
Raising the bar: What to expect from cardiovascular genetic testing in 2018?
“The genetic services of Blueprint Genetics were highly professional. Their results came in due time, together with a thorough and insightful interpretation, reflecting high professional standards. We were very pleased with this collaboration and wish to continue it.”
Published on June 12, 2018
The aim of the new panel is to increase the clinical utility and diagnostic yield for patients with a clinical suspicion of primary immunodeficiency (PID), especially for those patients where primary ciliary dyskinesia (PCD) is included in the differential diagnosis. In these cases, the core symptoms are often very similar…Read more
See all news
53rd Annual Congress of the Canadian Neurological Sciences Federation
1650 Argyle St, Halifax, NS B3J, Canada
The Canadian Neurological Sciences Federation will host the 53rd Annual Congress. This event will feature four days of accredited scientific courses to assist their members, and others, with their Continuing Professional Development and Maintenance of Certification. This is a collegial meeting providing multidisciplinary courses relevant to all neuroscience specialties. …Read more
See all events
CAP CLIA ISO15189
Blueprint Genetics is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory. Our Sequence Analysis is ISO 15189 accredited in every step from sample arrival to clinical interpretation. The ISO 15189 standard accreditation is carried by FINAS and the information about the scope is available on the website www.finas.fi/Documents/T292_A01_2016.pdf. Read more